Novo Nordisk's CagriSema linked to 25% weight loss in women in post hoc trial analysis
NVO•A post hoc analysis of Novo Nordisk's REDEFINE 1 obesity trial linked investigational CagriSema to 25% weight loss in women. The company said the once-weekly treatment combines semaglutide and cagrilintide; its U.S. application was filed in December 2025, with a decision expected in Q4 2026.
1. Trial analysis
Novo Nordisk presented two analyses of its REDEFINE 1 obesity trial at The Menopause Society 2026 Annual Meeting. CagriSema produced significant weight loss versus placebo across menopausal stages, along with reductions in waist circumference. Gastrointestinal side effects were mostly transient and mild to moderate, while treatment discontinuations were more common with CagriSema than placebo.
2. Application timeline
The once-weekly investigational treatment combines semaglutide with cagrilintide. A U.S. application was filed in December 2025, with a decision expected in Q4 2026.
